医院2012年至2016年保肝药物临床应用分析  

Clinical Application of Liver-Protecting Drugs in a Hospital from 2012 to 2016

作　　者：陈安妮[1] 孙慧慧[1] 王慧[1] 李洋[1] 方莎莎 王琳召 张国庆[1] Chen Anni;Sun Huihui;Wang hui;Li Yang;Fang Shasha;Wang Linzhao;Zhang Guoqing(Department of Pharmacy,Shanghai Eastern Hepatobiliary Surgery Hospital,Shanghai,China200438)

机构地区：[1]上海东方肝胆外科医院药材科,上海200438

出　　处：《中国药业》2018年第5期83-87,共5页China Pharmaceuticals

摘　　要：目的了解2012年至2016年医院患者保肝药物应用情况,分析其发展趋势,为临床合理应用提供参考。方法采用世界卫生组织推荐的限定日剂量分析方法,回顾性统计并分析医院2012年至2016年保肝药总销售金额、用药频度(DDDs)、限定日费用(DDC)。结果销售金额和用药频度均位于前10位的保肝药物分别为异甘草酸镁注射液、注射用还原型谷胱甘肽、注射用丁二磺酸腺苷蛋氨酸、谷胱甘肽片、多烯磷脂酰胆碱注射液、熊去氧胆酸胶囊、双环醇片、复方甘草酸苷片。异甘草酸镁注射液、门冬氨酸鸟氨酸注射液、注射用丁二磺酸腺苷蛋氨酸、苦黄注射液、促肝细胞生长素的DDC居高不下。结论医院保肝药物应用相对合理,符合安全、有效、经济的用药原则。Objective To understand the application and development trend of liver-protecting drugs for patients in our hospital 2012 to 2016,and provide clinical references for the rational drug use.Methods The consumption sum,DDDs and DDC of liver-protecting drugs were retrospectively analyzed by means of defined daily dose recommended by WHO.Results The top 10 liver-protecting drugs in the list of consumption sum and DDDs were Magnesium Isoglycyrrhizinate Injection,Reduced Glutathione for Injection,Ademetionine 1,4-Butanedisulfonate for Injection,Reduced Glutathione Tablets,Polyene Phosphatidylcholine Injection,Ursodeoxycholic Acid Capsules,BicycloI Tablets and Compound Glycyrrhizin Tablets.The DDC of Magnesium Isoglycyrrhizinate Injection,Injection,Ademetionine 1,4-Butanedi sulfonate for Injection,Kuhuang Injection,and Hepatocyte Growth-Promoting Factors Injection remained high.Conclusion The application of liver-protecting drugs in our hospital is relatively reasonable,which is in accordance with the medication principles of safety,effective and economic

关 键 词：保肝药物 合理用药 利用分析 用药频度 限定日费用 

分 类 号：R969.3[医药卫生—药理学] R975.5[医药卫生—药学]